David Boyer, MD, will present an update on Opthea’s wet AMD program, including highlights of the unmet medical need in wet AMD, the sozinibercept Phase 2b trial results, and the Phase 3 program ...
Ocugen said the Food and Drug Administration lifted a clinical hold on its OCU200 investigational treatment for diabetic macular edema, paving the way for Phase 1 trials.